title: A case report of orbital inflammatory syndrome secondary to ipilimumab.
abstract: Ipilimumab is a monoclonal antibody to cytotoxic T-lymphocyte antigen-4, a negative regulator of T-cell-mediated immune response. Ipilimumab is approved by the US Food and Drug Administration for the treatment of advanced melanoma. However, its use frequently has been associated with immune-related side effects, which can be explained by its mechanism of action. More common adverse effects include dermatitis, colitis, hepatitis, and endocrinopathies, but many less common immune-related adverse effects that involve various tissues and organ systems have been reported with more widespread use of ipilimumab since its approval in 2011. A case of bilateral orbital inflammatory syndrome secondary to ipilimumab, in a patient undergoing adjuvant treatment for metastatic melanoma, is reported.
authors.affiliation: Department of Ophthalmology, Georgia Regents University, Augusta, Georgia, U.S.A.
authors.forename: Amanda D
authors.initials: AD
authors.lastname: Henderson
authors.forename: Dilip A
authors.initials: DA
authors.lastname: Thomas
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D060908:CTLA-4 Antigen / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D000074324:Ipilimumab; D008207:Lymphatic Metastasis; D008279:Magnetic Resonance Imaging; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D016727:Orbital Pseudotumor / Q000139:chemically induced* / Q000175:diagnosis; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D000074324:Ipilimumab